We are live on ! Find out more
PBMWW

Psyence Biomedical Warrant

23 hedge funds and large institutions have $80.5K invested in Psyence Biomedical Warrant in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

46.98% more ownership

Funds ownership: 0%46.98% (+47%)

6% more capital invested

Capital invested by funds: $75.6K → $80.5K (+$4.85K)

18% less funds holding

Funds holding: 2823 (-5)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 5

Holders
23
Holders Change
-5
Holders Change %
-17.86%
% of All Funds
0.33%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
2
Reduced
1
Closed
5
Calls
$7K
Puts
Net Calls
+$7K
Net Calls Change
+$2K

PBMWW Hedge Fund Activity: Q3 2024 in Review

23 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Psyence Biomedical Warrant (PBMWW) for Q3 2024, worth a combined $80.5K — up 6.4% from $75.6K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of PBMWW and 0 opened new positions — a net loss of 5 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was Cowen and Company, adding an estimated $906. The largest seller was LMR Partners, exiting entirely with an estimated $3.5K sold.

  • 23 institutional investors held Psyence Biomedical Warrant (PBMWW) as of Q3 2024, down from 28 in Q2 2024.
  • Funds reported $80.5K of Psyence Biomedical Warrant stock for Q3 2024, up 6.4% quarter-over-quarter.
  • 0 funds opened new Psyence Biomedical Warrant positions in Q3 2024 and 5 closed out, a net change of -5 holders.
  • The largest Psyence Biomedical Warrant buyer in Q3 2024 was Cowen and Company, an estimated $906 added.
  • The largest Psyence Biomedical Warrant seller in Q3 2024 was LMR Partners, an estimated $3.5K sold.

Based on aggregated 13F filings for Q3 2024.